Pratley RE, Aroda VR, Lingvay I, Ldemann J, Andreassen C, Navarria A et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Always consult a healthcare provider if you have health concerns
Although rhGH-treatment partly restored reduced expression of GHR and IGF-1 in the kidneys and resulted in profound metabolic effects, including improved weight gain and lower urea serum levels, there was no difference with respect to renal recovery and mortality compared to placebo-treated controls
Tirzepatide (Mounjaro) a dual GIP/GLP-1 receptor agonist licensed by the MHRA for type 2 diabetes
Quarterly visits during maintenance: weight check, lab review, plan adjustment